60
Participants
Start Date
June 30, 2012
Primary Completion Date
July 31, 2013
subjects will receive either infliximab, adalimumab or etanercept
"The subjects receive treatment with a tnf-alfa blocking according to the official guidelines for the particular drug.~The study subjects will receive treatment with one drug only -~1. infliximab or~2. adalimumab or~3. etanercept~The consulting dermatologist decides which drug to use according to official guidelines"
RECRUITING
Copenhagen University Hospital Gentofte, Department of Skin and Allergies, Hellerup
RECRUITING
Karolinska Institute, Department of Medicine, Stockholm
Collaborators (1)
The Michaelsen Foundation
UNKNOWN
Pfizer
INDUSTRY
University Hospital, Gentofte, Copenhagen
OTHER